MAB858-4
抗RSV抗体，混合物，克隆号133-1H、131-2G和130-12H
ascites fluid, Chemicon®, from mouse
别名:
RSV
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
130-12H, monoclonal, 131-2G, monoclonal, 133-1H, monoclonal
Species reactivity:
human
Application:
ELISA, IF
Technique(s):
ELISA: suitable, immunofluorescence: suitable
Citations:
5
biological source
mouse
antibody form
ascites fluid
antibody product type
primary antibodies
clone
130-12H, monoclonal, 131-2G, monoclonal, 133-1H, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable, immunofluorescence: suitable
isotype
IgG
shipped in
wet ice
Quality Level
Analysis Note
对照
RSV对照玻片，目录号5012-5
RSV对照玻片，目录号5012-5
Application
ELISA（1:800+）
间接免疫荧光（1:100-200+）（新鲜冷冻组织切片）
最终工作稀释度必须由最终用户确定。
间接免疫荧光（1:100-200+）（新鲜冷冻组织切片）
最终工作稀释度必须由最终用户确定。
抗RSV抗体，混合物，克隆号133-1H、131-2G & 130-12H是抗呼吸道合胞病毒的抗体，用于IF、ELISA。
研究子类别
传染病 - 病毒
传染病 - 病毒
研究类别
传染病
传染病
Biochem/physiol Actions
MAB858-1、2和3的所有RSV规格的混合体。可识别A型和B型菌株的融合蛋白、G蛋白和核蛋白。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
General description
RSV是一种不稳定的副粘病毒，在组织培养中产生人类细胞的特征性融合-合胞体效应。已经鉴定出两种亚型A和B。亚型B的特征是该病毒的无症状株。更严重的临床疾病涉及亚型A株。
Immunogen
A2
Other Notes
浓度：请参考批次特异性浓缩物的检验报告。
Physical form
未纯化
腹水液。
Preparation Note
自收到之日起在-20°C可稳定保存1年。等分以避免反复冻融。为了最大程度地回收产品，在融化后和取下盖子之前，将原始小瓶进行离心。
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Talita Bianca Gagliardi et al.
Intervirology, 60(1-2), 56-60 (2017-09-05)
Syncytia formation is the hallmark of the cytopathic effect caused by human respiratory syncytial virus (HRSV), which is the most important viral respiratory pathogen in children. This article reports methodological improvements in primary HRSV isolation and the importance of syncytia
Tiina Talts et al.
Microbiology spectrum, 12(4), e0306723-e0306723 (2024-02-27)
Prevention of respiratory syncytial virus (RSV) infection is now a global health priority, with a long-acting monoclonal antibody and two RSV vaccines recently licenced for clinical use. Most licenced and candidate interventions target the RSV fusion (RSV-F) protein. New interventions
John P DeVincenzo et al.
The Journal of infectious diseases, 190(5), 975-978 (2004-08-06)
Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV
Ziyin Wang et al.
Mucosal immunology, 17(2), 272-287 (2024-02-22)
Respiratory viral infections remain a major cause of hospitalization and death worldwide. Patients with respiratory infections often lose weight. While acute weight loss is speculated to be a tolerance mechanism to limit pathogen growth, severe weight loss following infection can
Hayat Caidi et al.
Methods in molecular biology (Clifton, N.J.), 1442, 13-32 (2016-07-29)
Defective interfering viral particles have been reported as important determinants of the course of viral infection, and they can markedly temper the virulence of the infection. Here, we describe a simple method, based on limiting dilution, for the removal of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持